Pluristem Therapeutics Presents Three Month Follow-Up Data from First Patient to Receive Placental Derived PLX-PAD at Two Meetings in Germany and France

Presentations also Address the Strategic Partnerships in the Life Science Industry and the Development of PLX Cells for the Treatment of Intestinal Disease


 

HAIFA, Israel--(BUSINESS WIRE)--Nov 19, 2009 - Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT) today announced that it will present three month follow-up data from the first patient to receive PLX-PAD at both the 1st Annual Conference of the German-Israeli Life Science Committee at the Life Science Center in Düsseldorf, Germany and at the DigestScience Congress in Lille, France. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the company's leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).


 

Zami Aberman, chairman and CEO of Pluristem, will present the data at the 1st Annual Conference of the German-Israeli Life Science Committee, in the content of a presentation on how to establish and execute successful strategic partnerships with global life science industry leaders, at 2:30 p.m. CET, Nov. 20, 2009. Dr. Frida Grynspan, VP Research and Development, will present the data and address the development of human placenta derived PLX cells for the treatment of intestinal disease at the DigestScience Congress, at 10:15 a.m. CET, Nov. 20, 2009.


 

“These early results are encouraging and we look forward to more data from this dose level to further assess the safety and efficacy of PLX-PAD,” said Mr. Aberman.


 

Dr. Grynspan said, “Pluristem's PLX cells demonstrate favorable characteristics not only for the treatment of PAD but also for the treatment of a variety of other disorders. Pluristem has a completed proof-of-principle study testing PLX-IBD for the treatment of Crohn's disease and ulcerative colitis, known collectively as inflammatory bowel disease, IBD.”


 

PLX-IBD cells were administered in vivo to mice in which inflammatory bowel disease was induced using the intra-rectal administration of trinitrobenzene sulphonic acid (TNBS). There was a statistically significant improvement in a standard inflammatory histological score in those animals given PLX-IBD intravenously compared to vehicle controls or those animals receiving daily treatment with five-aminosalicylic acid.


 

About the 1st Annual Conference of the German-Israeli Life Science Committee


 

The 1st Annual Conference of the German-Israeli Life Science Committee will focus on how small and medium size German and Israeli enterprises can maximize their chances to establish and execute a successful strategic partnership with global life science industry leaders from Germany and Israel. The speakers at the workshop associated with the committee meeting will include Dr. Simone Botti – Chairman GILSC, Dr. Ulrich Betz – Head, Strategic Innovation & Research Portfolio Management MerckSerono, Dr. Alexander Schachtrupp - Head, Medical Research BBraun, Dr. Manfred Baier – Head, Roche Applied Sciences and Mr. Zami Aberman – Chairman & CEO Pluristem Therapeutics Inc.


 

About the DigestScience Congress


 

The DigestScience Congress in Lille France will address the cutting edge of cell therapy in IBD.


 

About Pluristem


 

Pluristem is a clinical stage biotechnology company with proprietary technology for the development and manufacturing of standardized cell therapies derived from the human placenta. Pluristem's patented and scalable PLX (PLacental eXpanded) cell product candidates are developed as readily available for the treatment of critical limb ischemia (CLI) and other diseases.


 

See our product animation on YouTube: Animation, the content of which is not part of this press release.


 

Safe Harbor Statement


 

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, when we say that these early results are encouraging and we look forward to more data from this dose level to further assess the safety and efficacy of PLX-PAD, or that Pluristem's PLX cells demonstrate favorable characteristics not only for the treatment of PAD but also for the treatment of a variety of other disorders, we are using forward-looking statements. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching our clinical trials; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.


 

For more information visit our website at www.pluristem.com, the content of which is not part of this press release.


 

 


 

 


 

Contact: Pluristem Therapeutics Inc.

William Prather RPh, MD, +1-303-883-4954

Sr. VP Corporate Development

William.PratherMD@pluristem.com

or

Russo Partners

Andreas Marathovouniotis, +1-212-845-4235

andreas.marathis@russopartnersllc.com


 

 

Posted: November 2009

View comments

Hide
(web4)